Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month Low – What’s Next?

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reached a new 52-week low during trading on Tuesday . The stock traded as low as $555.30 and last traded at $559.72, with a volume of 465172 shares traded. The stock had previously closed at $572.78.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of analyst reports. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $966.88.

Regeneron Pharmaceuticals Stock Down 2.8 %

The business’s fifty day moving average price is $674.46 and its two-hundred day moving average price is $772.53. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market cap of $60.87 billion, a P/E ratio of 14.55, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.86 earnings per share. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.63%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of REGN. Integrated Wealth Concepts LLC lifted its position in shares of Regeneron Pharmaceuticals by 40.1% during the third quarter. Integrated Wealth Concepts LLC now owns 748 shares of the biopharmaceutical company’s stock worth $786,000 after purchasing an additional 214 shares in the last quarter. Kovitz Investment Group Partners LLC grew its holdings in Regeneron Pharmaceuticals by 54.6% during the 3rd quarter. Kovitz Investment Group Partners LLC now owns 3,691 shares of the biopharmaceutical company’s stock worth $3,880,000 after acquiring an additional 1,303 shares during the period. EP Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 16.6% during the 3rd quarter. EP Wealth Advisors LLC now owns 1,467 shares of the biopharmaceutical company’s stock worth $1,542,000 after acquiring an additional 209 shares during the period. MML Investors Services LLC lifted its stake in shares of Regeneron Pharmaceuticals by 13.9% in the 3rd quarter. MML Investors Services LLC now owns 5,315 shares of the biopharmaceutical company’s stock valued at $5,587,000 after purchasing an additional 648 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $9,908,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.